

Transaction Contacts

Coverage Team:
Gabriel Cavazos
Brian Swanson

ECM Team:
Rahul Chaudhary
Patrick Morley



SVB Securities Serves as Lead-Left Bookrunner for Axsome Therapeutics' (Nasdaq: AXSM) \$225 Million Follow-On Offering

Key Transaction Highlights

- Confidentially marketed deal that publicly launched Tuesday, June 27th post-close and priced Wednesday, June 28th pre-open
- Deal consisted of 3,000,000 shares of common stock at a price of \$75.00 per share, representing a 10.0% discount to last sale.
- Well oversubscribed from both new and existing investors
- Axsome intends to use the proceeds from this offering to advance its late-stage pipeline, including funding existing and potential new clinical programs, products, and product candidates, to expand its commercialization efforts, and for other general corporate purposes.
- This is SVB Securities' 2nd bookrun offering for Axsome and 33rd bookrun equity offering in 2023.

If you would like to unsubscribe from this distribution, click [here](#). If you would like to unsubscribe from all SVB Securities distributions, click [here](#).

THIS EMAIL IS FOR INFORMATIONAL PURPOSES ONLY AND IS BEING FURNISHED TO INVESTMENT BANKING CLIENTS OF SVB SECURITIES LLC. THE INFORMATION INCLUDED HEREIN IS FOR YOUR INFORMATION ONLY AND MAY NOT BE REPRODUCED FOR OR REDISTRIBUTED TO ANY OTHER PURPOSES. THESE SECURITIES HAVE BEEN SOLD. THIS EMAIL IS NOT AN OFFER TO SELL, AND IS NOT SOLICITING AN OFFER TO BUY, ANY SECURITIES.

BOSTON
53 State Street
40th Floor
Boston, MA 02109

CHARLOTTE
2151 Hawkins Street
Suite 1025
Charlotte, NC 28203

NASHVILLE
40 Burton Hills Boulevard
Suite 200
Nashville, TN 37215

NEW YORK
1301 Avenue of the Americas
12th Floor
New York, NY 10019

SAN FRANCISCO
255 California Street
12th Floor
San Francisco, CA 94111

An SVB Company
svbsecurities.com